Cargando…
BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease to treat. Despite advances in surgical techniques, radiation, and medical therapies, the 5-year survival rate remains below 9%. Over the past decade, the genomic landscape of PDAC has been well studied and BRCA mutations have emer...
Autores principales: | Wong, Winston, Raufi, Alexander G, Safyan, Rachael A, Bates, Susan E, Manji, Gulam A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185320/ https://www.ncbi.nlm.nih.gov/pubmed/32368150 http://dx.doi.org/10.2147/CMAR.S211151 |
Ejemplares similares
-
Current and Future Prospective of Injectable Hydrogels—Design Challenges and Limitations
por: Almawash, Saud, et al.
Publicado: (2022) -
Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge
por: Keane, Fergus, et al.
Publicado: (2023) -
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010) -
Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review
por: Raufi, Ali, et al.
Publicado: (2017) -
Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia
por: Briceño-Balcázar, Ignacio, et al.
Publicado: (2017)